Neurotech International Limited
On 12 September 2016 (“Prospectus Date”), Neurotech International Limited (ACN 610 205 402) (“Neurotech” or “the Company”) lodged a prospectus (“Prospectus”) with the Australian Securities and Investments Commission (“ASIC”) for the offer of 35,000,000 fully paid ordinary shares in the Company (“Shares”) at an issue price of 20 cents per Share to raise $7,000,000, and the offer of up to 2,529,076 options to acquire Shares to the Lead Manager (as those terms are defined in the Prospectus).
THE OFFER HAS NOW CLOSED, AND THE COMPANY IS NO LONGER ACCEPTING APPLICATIONS FOR SHARES.
An electronic copy of the Prospectus can be obtained in PDF format by clicking below after confirming agreement to the following.
This is an important document that should be read in its entirety. If you do not understand it, you should consult your professional adviser without delay. The paper form of the electronic Prospectus is accessible through this website has been lodged with ASIC.
Applications for securities referred to in the Prospectus must be made in accordance with the terms and conditions set out in the Prospectus. Applications for securities must be made on an application form that accompanies a complete hard copy of the Prospectus. There is no facility for online applications.
The Company will not issue any Shares on the basis of this Prospectus later than 13 months after the Prospectus Date.
The Prospectus does not constitute an offer in any place in which, or to any person to whom, it will not be lawful to make such an offer. No action has been taken to lodge, register or file the Prospectus in any jurisdiction outside Australia. The distribution of this Prospectus outside Australia may be restricted by law and persons who come into possession of this Prospectus outside Australia should seek advice on and observe any such restrictions. The investment described in this Prospectus has not been recommended by any regulatory authority of any jurisdiction including ASIC.
The information on this website is provided for information purposes only and is subject to change without notice. Nothing contained on this website or in the Prospectus constitutes investment, legal, accounting, business, tax or other advice. The information on this website and in the Prospectus does not take into account your investment objectives, financial situation or particular needs. The information on this website does not form part of the Prospectus.
By accessing the Prospectus, you are taken to have confirmed that you have read and understood the notice and agree to these terms and conditions.
Mark Davies - Chairman
Mark Davies graduated from the University of Western Australia with a Bachelor of Commerce. He has over 20 years’ experience in trading, investment banking and providing corporate advice. He worked at Montagu Stockbrokers before co-founding investment banking firm Cygnet Capital and more recently 1861 Capital.
Mark specialises in providing corporate advice and capital raising services to emerging companies seeking business development opportunities and funding from the Australian market.
Peter J.L. Griffiths - Chief Executive Officer
Peter J.L. Griffiths, B.Sc. (Hons), draws on his more than 20 years of leadership experience in the software industry.As EVP and Group Executive at CA Technologies, he was responsible for investment and strategy across the five business units that drove the company’s leadership in IT Management Cloud, Application Development, Operations, DevOps and Security for enterprise and growth markets. As a member of the company’s Executive Management Team; Mr Griffiths also oversaw all aspects of Operations, M&A activity, Industry Solutions, and the CA Technologies Innovation Center, driving mobile-first software products and the transition to SaaS offerings and business models.
Before CA Technologies, Mr Griffiths was Vice President, WW Business Analytics and Applications for IBM, a key driver in building the Business Analytics division within IBM Software Group, including the acquisition and integration of SPSS, Clarity, OpenPages and Cognos.
Prior to IBM, Mr Griffiths served on the executive team at Cognos, Inc. a global leader of Business Intelligence, Business Analytics and Performance Management software, where he was SVP of Products over the companies 10 year growth phase to $1B in revenue and the subsequent sale of Cognos to IBM in 2008.
Mr Griffiths joined Cognos in 1998 upon its acquisition of Relational Matters PLC, a data analytics company where he was co-founder and CEO. Mr Griffiths has also held positions in management consulting and in the financial services industry.
Mr Griffiths is a member of the Board of Directors of Lavastorm Analytics and the Board of Trustees of the Anita Borg Institute and also acts as an Investment Board Advisor to Ottawa-based Mistral Ventures and New York-based Bridge Growth Capital. He earned a Bachelor of Science degree in Electronic Engineering with 1st Class Honors from Brighton University in England.
Dr David S Cantor - Non-Executive Director
A highly distinguished clinician, neuroscientist, program developer and a member of the Company’s Scientific Advisory Board, Dr Cantor’s career spans more than 40 years in the academic and clinical neuroscience sector.
He is currently the CEO and Clinical Director of Mind and Motion Developmental Centers of Georgia, a multidisciplinary treatment facility providing a range of diagnostic and treatment services to children and adults seeking help with neurological disorders such as autism, ADHD, traumatic brain injury and sensory processing disorders. He is also the CEO and Managing Partner of BrainDx, an international software company that produces functional brain analytic software through computer assisted quantitative EEG (QEEG) reports and big database measures of brain development.
In addition to the above, Dr Cantor has held multiple board positions across various neuroscientific associations, including being a founding board member and current Chairman of the International Board of Quantitative Electrophysiology, established to maintain the highest quality of resources and examination procedures for clinicians and academicians with interests in quantitative electrophysiology. He is also Secretary of the International Society of Neurofeedback and Research and an advisory board member of the Innovative Health Foundation.
Winton Willesee - Non-executive Director
Mr Willesee is an experienced company director and company secretary. Mr Willesee has considerable experience with ASX listed and other companies over a broad range of industries having been involved with many successful ventures from early stage through to large capital development projects.
Mr Willesee holds a Master of Commerce, a Post-Graduate Diploma in Business (Economics and Finance), a Graduate Diploma in Applied Finance and Investment, a Graduate Diploma in Applied Corporate Governance, a Graduate Diploma in Education and a Bachelor of Business. He is a Fellow of the Financial Services Institute of Australasia, a Graduate of the Australian Institute of Company Directors, a Member of CPA Australia and a Fellow of the Governance Institute of Australia and the Institute of Chartered Secretaries and Administrators/Chartered Secretary.
Erlyn Dale - Company Secretary
Ms Dale is an experienced company secretary, having held positions as company secretary for a number of ASX listed public companies across a diverse range of industries including resources, technology, industrials and health care.
Ms Dale has completed a Bachelor of Commerce (Accounting and Finance) and a Graduate Diploma of Applied Corporate Governance and is an Associate Member of both the Institute of Chartered Secretaries and Administrators and the Governance Institute of Australia.